peptidylprolyl isomerase A pseudogene 79Genealiases: []
Q-omics provides the consensus-scored PPIAP79 profile across patient tissues and cancer cell-line models. PPIAP79 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, PPIAP79 is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, PPIAP79 RNA expression shows 5,947 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUSC, HNSC, and STAD as cancer lineages where PPIAP79 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIAP79 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIAP79 survival associations across molecular data types. PPIAP79 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIAP79 RNA expression–survival associations across cancer types. High PPIAP79 expression shows unfavorable associations in READ, ACC and STAD, but favorable associations in LUSC, UCS and ESCA. The LUSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for PPIAP79 RNA expression.
This table summarizes PPIAP79 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PPIAP79. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIAP79 shows lower tumor expression in PAAD and KICH and higher tumor expression in HNSC and KIRC. The HNSC box plot shows higher PPIAP79 RNA expression in tumor versus normal tissue (log2 FC = +0.091, t-test p = .024).
This table shows molecular features associated with PPIAP79 in patient tissues and cancer cell lines. In patient samples, PPIAP79 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
